BioequivalenceGlide Octreotide is equivalent to liquid injection - A Phase 1 clinical study using Octreotide in the Glide technology demonstrated successful bioequivalence.
Controlled Release of FormulationsControl and sustained delivery of injectable drugs is a growth area in the pharmaceutical industry. Glide Pharma are developing formulations with tuneable release profiles through its formulation strategies and manufacturing processes.
Flu VaccineDelivery of Flu vaccine using the Glide SDI - A flu vaccine study using the Glide technology demonstrated bioequivalence and the possibility of dose sparing.
Peptide StabilityRoom temperature stable peptide formulations - Stable peptide formulations have been developed using a formulation design strategy that combines stabilising and structural matrices in the Glide formulation.
Conjugated InsulinA successful collaboration held with Lipoxen on a feasibility study to use PSA insulin with the Glide Technology can be found in an abstract 'Development and testing of solid dose formulations containing polysialic acid insulin conjugate: next generation of long-acting insulin'.
